Greenwich LifeSciences, Inc.
NASDAQ:GLSI · NASDAQ Capital Market
+$1.03 today
Vol 0.13M · Avg 0.15M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-1081.2%
avg -188.4%
ROIC
154.8%
avg 31.4%
ROA
287.3%
avg -2283.5%
Analysis
ROA is currently the strongest return metric at 287.3% versus its period average of -2283.5%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Snehal S. Patel | Chief Executive Officer, Chief Financial Officer & Director | $1.10M | — | 62 | $5.60M | 38.18% |
Eric Rothe | Founder & Independent Director | $65,636.00 | — | 51 | $82,698.00 | 0.56% |
Christine T. Fischette | Vice President of Business Development | — | — | 75 | — | — |
Frank Joseph Daugherty | Chief Medical Officer & Director | — | — | 75 | $209,780.00 | 1.43% |
Jaye L. Thompson | Vice President Clinical & Regulatory Affairs | — | — | 60 | $299,636.00 | 2.04% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$489,325.00
Sells
0
$0.00
Net Sentiment
+$489,325.00
Net buying
Most Active
Patel Snehal
8 transactions
Analysis
Insiders reported 8 buys worth $489,325.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $489,325.00. Patel Snehal was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Immix Biopharma, Inc.
NASDAQ:IMMX
$459.70M
Opus Genetics, Inc.
NASDAQ:IRD
$328.84M
Surrozen, Inc.
NASDAQ:SRZN
$174.90M
TuHURA Biosciences, Inc.
NASDAQ:HURA
$147.74M
Agenus Inc.
NASDAQ:AGEN
$137.42M
Seer, Inc.
NASDAQ:SEER
$94.57M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$89.03M
Oncolytics Biotech Inc.
NASDAQ:ONCY
$80.59M
Tevogen Bio Holdings Inc.
TVGN
$43.84M
Atossa Therapeutics, Inc.
ATOS
$21.18M
Who manages GLSI?
Greenwich LifeSciences, Inc. (GLSI) lists 5 active executives. The top listed executive is Snehal S. Patel, Chief Executive Officer, Chief Financial Officer & Director.
Are GLSI insiders buying or selling?
Recent insider activity shows net buying of $28.95M.
Explore More
Continue the stock analysis
Jump to another research area for this company.